Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD59GI)

• Drug Name: Urapidil Drug Info
• Synonyms: urapidil; 34661-75-1; Ebrantil; Eupressyl; Mediatensyl; Uraprene; Urapidilum [INN-Latin]; UNII-A78GF17HJS; NSC 310405; B-66256; C20H29N5O3; EINECS 252-130-4; BRN 0725782; A78GF17HJS; MLS003115907; 6-(3-(4-(o-Methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil; 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil; NCGC00016066-07; Ebrantil (TN); 6-((3-(4-(o-Methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyluracil; W-106718; Urapidilum; urapidil(jan); TgAAV-TNFR:Fc

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
Inflammation	1A00-CA43.1	Phase 1/2	[2]

• Cross-matching ID:
  PubChem CID: 5639
  ChEBI ID: CHEBI:32278
  CAS Number: CAS 34661-75-1
  TTD Drug ID: DMD59GI

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[4]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[5]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[6]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[7]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[8]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[9]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[10]
Treximet	DMU54QB	Migraine	8A80	Approved	[11]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[12]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[13]

Drug(s) Targeting Adrenergic receptor Alpha-1 (ADRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[14]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[14]
Prazosin	DMCD9YG	Benign prostatic hyperplasia	GA90	Approved	[15]
Ergotamine	DMKR3C5	Cluster headache	8A81.0	Approved	[16]
Midodrine	DME2PY5	Orthostatic hypotension	BA21	Approved	[17]
Phenylpropanolamine	DMTFK3O	Allergic rhinitis	CA08.0	Withdrawn from market	[18]
Metazosin	DMAZ28C	Cardiac disease	BA00-BE2Z	Discontinued in Phase 3	[19]
DC-015	DMCDMWJ	N. A.	N. A.	Terminated	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Agonist	[3]
Adrenergic receptor Alpha-1 (ADRA1)	TTG28O6	NOUNIPROTAC	Antagonist	[3]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
• [3] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [6] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [7] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [8] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [9] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [10] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [13] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [14] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [15] Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33.
• [16] Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6.
• [17] Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505.
• [18] Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35.
• [19] Metazosin tablets (Kenosin) in the treatment of chronic congestive heart failure. Cas Lek Cesk. 1995 Sep 20;134(18):590-3.
• [20] Antihypertensive and Hypolipidemic Effects of DC-015, a Novel, Potent and Specific alpha(1)-Adrenoceptor Antagonist: Comparison with Prazosin in Spontaneously Hypertensive Rats. J Biomed Sci. 1996 Apr;3(2):108-116.